TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01019499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: berry products
Description: effects of berry consumption on cardiovascular indicators~two portions daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control products
Description: two portions daily
Study: NCT04805359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise
Description: Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
Study: NCT00555997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo
Study: NCT01239836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constructivist interactive workshop on urinary incontinence
Description: A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constructivist interactive workshop on urinary incontinence
Description: A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based self-management tool
Description: Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based self-management tool
Description: Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General health lecture
Description: Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
Study: NCT02358980

Intervention type: DEVICE
Intervention: KIDNEY therapy
Study: NCT02508571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct swallowing training (DST)
Description: The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct swallowing training (DST)
Description: The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor stimulation (OSMS)
Description: The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
Study: NCT00003162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01580995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir 500 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study: NCT04278495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar (Losartan Potassium 25mg)
Description: Cozaar (Losartan Potassium 25mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04083937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with photons
Description: hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with protons
Description: hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normofractionated radiotherapy with photons
Description: normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
Study: NCT00275301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
Study: NCT02361879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
Study: NCT02508571

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham intervention
Description: The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
Study: NCT01939210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in breathing training sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Participate in breathing training sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00571077

Intervention type: DEVICE
Intervention: Electrical Impedance Scanning (EIS) of the Thyroid gland
Description: Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
Study: NCT02137499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko device
Description: Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
Study: NCT01845649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3011 Estradiol Vaginal Cream
Description: Daily for 14 days followed by 3 times per week for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Daily for 14 days followed by 3 times per week for 10 weeks
Study: NCT01310712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 5 mg every 12 hours for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice a day for 42 days.
Study: NCT00816647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellofemoral stabilizing surgery
Description: Comparison of surgical techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellofemoral stabilizing surgery
Description: Comparison of surgical techniques
Study: NCT02151630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvic acid
Study: NCT01577719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lifestyle Improvement
Description: * Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
Study: NCT01074723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-cryptoxanthin and phytosterols
Description: Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-cryptoxanthin and phytosterols
Description: Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: b-cryptoxanthin and phytosterols
Description: Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
Study: NCT02151630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic Acid
Study: NCT01984749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8.
Study: NCT04252300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin + BAY1817080
Description: A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
Study: NCT02288364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine plus sodium bicarbonate
Study: NCT00513058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
Study: NCT00349622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT02151643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT20
Description: Modified ferric oxide adipate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT20
Description: Modified ferric oxide adipate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT20
Description: Modified ferric oxide adipate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT20
Description: Modified ferric oxide adipate tablets
Study: NCT01195181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon plus ribavirin
Description: peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon plus ribavirin
Description: peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
Study: NCT04126642

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment only group
Description: Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
Study: NCT02384109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with pharmacists
Description: Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care from primary care providers
Description: Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
Study: NCT03040505

Intervention type: OTHER
Intervention: questionnary
Description: Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.

Intervention type: OTHER
Intervention: questionnary
Description: Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
Study: NCT01343992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Patients will rest in bed ten minutes after the embryo transfer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No bedrest
Description: Patients will not rest in bed after the embryo transfer.
Study: NCT01861873

Intervention type: OTHER
Group type: OTHER
Intervention: measuring liver function by 18-FDGal PET/CT
Study: NCT06531629

Intervention type: PROCEDURE
Intervention: Surgery, radiation therapy and chemotherapy
Description: Surgery, radiation therapy and chemotherapy
Study: NCT02151643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to each PT20 dose arm
Study: NCT03819751

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI-targeted prostate biopsy
Description: All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
Study: NCT00460564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: botulinum toxin type A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01709123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chromium niacinate
Description: 200ug or 500ug supplementation in pill form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill for chromium niacinate
Study: NCT04669002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
Study: NCT00948415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Shape Up RI Campaign
Description: The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
Study: NCT02893111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
Study: NCT05633277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol
Description: Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polidocanol
Description: Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
Study: NCT01665677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: 40 mg PO daily
Study: NCT04249518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videoeducation
Description: No drugs used. The only difference in the to arms is the way the extradition is.